{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T21:46:55Z","timestamp":1778449615352,"version":"3.51.4"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aarhus University","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,1,28]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is associated with significantly increased morbidity and mortality. No specific treatment of the underlying condition is available for the majority of patients, but ACE-inhibitors (ACE-I) and angiotensin II-receptor blockers (ARB) slows progression in albuminuric CKD. Adding a mineralocorticoid receptor-antagonist (MRA) like spironolactone has an additive effect. However, renin\u2013angiotensin\u2013aldosterone system (RAAS)-blockade increases the risk of hyperkalaemia which is exacerbated by the presence of CKD. Thus, hyperkalaemia may prevent optimal use of RAAS-blockade in some patients.<\/jats:p>\n                    <jats:p>This project hypothesises that adding a potassium binder (patiromer) allows for improved RAAS-blockade including the use of MRA, thereby reducing albuminuria in patients with albuminuric CKD where full treatment is limited by hyperkalaemia.<\/jats:p>\n                    <jats:p>If successful, the study may lead to improved treatment of this subgroup of patients with CKD. Furthermore, the study will examine the feasibility of potassium binders in patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      An open-label, randomised controlled trial including 140 patients with estimated glomerular filtration rate (eGFR) 25\u201360\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      , a urinary albumin\/creatinine ratio (UACR) &gt;500\u2009mg\/g (or 200\u2009mg\/g if diabetes mellitus) and a current or two previous plasma-potassium &gt;4.5\u2009mmol\/L. Patients who develop hyperkaliaemia &gt;5.5\u2009mmol\/L during a run-in phase, in which RAAS-blockade is intesified with the possible addition of spironolactone, are randomised to 12-month treatment with maximal tolerated ACE-I\/ARB and spironolactone with or without patiromer.\n                    <\/jats:p>\n                    <jats:p>The primary endpoint is the difference in UACR measured at randomisation and 12 months compared between the two groups. Secondary endpoints include CKD progression, episodes of hyperkalaemia, blood pressure, eGFR, markers of cardiovascular disease, diet and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study is approved by The Central Denmark Region Committees on Health Research Ethics (REFNO 1-10-72-110-20) and is registered in the EudraCT database (REFNO 2020-001595-15). Results will be presented in peer-reviewed journals, at meetings and at international conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057503","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:29:46Z","timestamp":1645446586000},"page":"e057503","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Can patiromer allow for intensified renin\u2013angiotensin\u2013aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-338X","authenticated-orcid":false,"given":"Frederik Husum","family":"M\u00e5rup","sequence":"first","affiliation":[{"name":"Dept. of Biomedicine, Aarhus University, Aarhus, Denmark"},{"name":"Dept. of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Daugaard","family":"Peters","sequence":"additional","affiliation":[{"name":"Dept. of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Dept. of Clinical Medicine, Aarhus University, Aarhus, Midtjylland, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeppe Hagstrup","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Aalborg University Hospital, Aalborg, North Denmark Region, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[{"name":"Dept. of Biomedicine, Aarhus University, Aarhus, Denmark"},{"name":"Dept. of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"2025121508220076000_12.2.e057503.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745"},{"key":"2025121508220076000_12.2.e057503.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.07.007"},{"key":"2025121508220076000_12.2.e057503.3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11906-003-0088-8","article-title":"How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?","volume":"5","author":"Weinberg","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"2025121508220076000_12.2.e057503.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"2025121508220076000_12.2.e057503.5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121508220076000_12.2.e057503.6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National kidney Foundation in collaboration with the US food and drug administration and European medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"American Journal of Kidney Diseases"},{"key":"2025121508220076000_12.2.e057503.7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MNH.0000000000000541","article-title":"Change in albuminuria as a surrogate endpoint","volume":"28","author":"Waijer","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025121508220076000_12.2.e057503.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.031"},{"key":"2025121508220076000_12.2.e057503.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00200.x"},{"key":"2025121508220076000_12.2.e057503.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01138-4"},{"key":"2025121508220076000_12.2.e057503.11","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.69"},{"key":"2025121508220076000_12.2.e057503.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcm.2019.01.007","article-title":"Endothelin-1 levels and cardiovascular events","volume":"30","author":"Jankowich","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"2025121508220076000_12.2.e057503.13","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0891"},{"key":"2025121508220076000_12.2.e057503.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"2025121508220076000_12.2.e057503.15","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200106000-00023"},{"key":"2025121508220076000_12.2.e057503.16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025121508220076000_12.2.e057503.17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"key":"2025121508220076000_12.2.e057503.18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.505"},{"key":"2025121508220076000_12.2.e057503.19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101079"},{"key":"2025121508220076000_12.2.e057503.20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1978.114"},{"key":"2025121508220076000_12.2.e057503.21","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1982.14"},{"key":"2025121508220076000_12.2.e057503.22","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0575"},{"key":"2025121508220076000_12.2.e057503.23","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2025121508220076000_12.2.e057503.24","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0337-0"},{"key":"2025121508220076000_12.2.e057503.25","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121508220076000_12.2.e057503.26","doi-asserted-by":"crossref","unstructured":"Weiss JN , Qu Z , Shivkumar K . Electrophysiology of hypokalemia and hyperkalemia. In: Circulation: arrhythmia and electrophysiology. vol 10, 2017.","DOI":"10.1161\/CIRCEP.116.004667"},{"key":"2025121508220076000_12.2.e057503.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.168"},{"key":"2025121508220076000_12.2.e057503.28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"2025121508220076000_12.2.e057503.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00258.x"},{"key":"2025121508220076000_12.2.e057503.30","first-page":"S27","article-title":"Managing hyperkalemia in high-risk patients in long-term care","volume":"23","author":"Kumar","year":"2017","journal-title":"Am J Manag Care"},{"key":"2025121508220076000_12.2.e057503.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"2025121508220076000_12.2.e057503.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"2025121508220076000_12.2.e057503.33","doi-asserted-by":"crossref","first-page":"A490","DOI":"10.1016\/j.jval.2017.08.519","article-title":"A cost-utility analysis of Raasi Enabling-Patiromer in patients with hyperkalemia","volume":"20","author":"Sutherland","year":"2017","journal-title":"Value in Health"},{"key":"2025121508220076000_12.2.e057503.34","doi-asserted-by":"crossref","DOI":"10.3390\/nu10030261","article-title":"Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function","volume":"10","author":"Cupisti","year":"2018","journal-title":"Nutrients"},{"key":"2025121508220076000_12.2.e057503.35","unstructured":"Official Journal of the internatiOnal Society of nephrology KDIGO . Clinical practice guideline for the management of blood pressure in chronic kidney disease, 2012. Available: http:\/\/www.kidney-international.org [Accessed 10 Jan 2022]."},{"key":"2025121508220076000_12.2.e057503.36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001982"},{"key":"2025121508220076000_12.2.e057503.37","doi-asserted-by":"publisher","DOI":"10.2307\/2684968"},{"key":"2025121508220076000_12.2.e057503.38","first-page":"308","volume-title":"Proceedings of the nutrition Society","volume":"76","author":"Woodside","year":"2017"},{"key":"2025121508220076000_12.2.e057503.39","doi-asserted-by":"crossref","first-page":"205031211667172","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: Scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med"},{"key":"2025121508220076000_12.2.e057503.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1113-8","article-title":"Validity of an online 24-h recall tool (myfood24) for dietary assessment in population studies: comparison with biomarkers and standard interviews","volume":"16","author":"Wark","year":"2018","journal-title":"BMC Med"},{"key":"2025121508220076000_12.2.e057503.41","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.06.016"},{"key":"2025121508220076000_12.2.e057503.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121508220076000_12.2.e057503.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121508220076000_12.2.e057503.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32135-X"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:22:09Z","timestamp":1765815729000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bmjopen-2021-057503"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057503","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}